News

2024-05-15
Strategic Collaboration - Exactis Innovation and PeriPharm
Exactis Innovation and PeriPharm Forge Strategic Collaboration to Advance Real-World Evidence Studies

2023-05-11
PROxy Brochure

Generation of Real-World Evidence to Better Inform Decision-Making This innovative PRO platform allows conducting real-world evidence studies in a timely manner.

2023-05-08
Proud to be Sponsoring the 2023 CADTH Symposium!

PeriPharm is proud to be a platinum sponsor at the CADTH 2023 Symposium to be held in Ottawa from May 16 to 18.

2023-04-19
New Publication

A study evaluating, from a Canadian perspective, the impact of fixed-duration targeted therapies on the economic burden of chronic lymphocytic leukemia.

Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada

2022-10-08
New Publication

A study evaluating, from a Canadian perspective, the economic impact of venetoclax in combination with azacitidine for the treatment of patients with acute myeloid leukemia.

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis

2021-11-30
Proud to Attend ISPOR Europe 2021 Virtual Conference!

PeriPharm is proud to attend and present some collaborations at the ISPOR Europe 2021 virtual conference which will be held from November 30 to December 3.

2021-05-17
Proud to Attend ISPOR 2021 Virtual Conference!

PeriPharm is proud to attend and present some collaborations at the ISPOR 2021 virtual conference held in May 2021.

2021-04-25
Proud to Attend AMMI Canada - CACMID 2021 Annual Virtual Conference!
PeriPharm is proud to attend and present some collaborations at the Association of Medical Microbiology and Infectious Disease Canada (AMMI Canada) 2021 annual virtual conference which will be held from April 25 to 30.
2021-02-15
New Publication

Presenting an impactful pan-Canadian collaboration in the treatment of CLL !

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada

2021-01-25
New Publication

A network meta-analysis by our team focussing on the treatment of glaucoma !

Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis

2020-11-16
Proud to Attend ISPOR Europe 2020 Virtual Conference!

PeriPharm is proud to attend and present some collaborations at the ISPOR 2020 virtual conference which will be held from November 16 to 19.

2020-07-06
New Publication

Fresh from the press: a new publication presenting real-world evidence !

Real-World Experience With Apremilast in the Treatment of Adults With Moderate to Severe Plaque Psoriasis in Québec: A Claims-Based Analysis of Drug Utilization and Healthcare Resource Utilization

2020-06-16
Network Meta-Analysis Brochure

Network meta-analysis (NMA) is used to estimate the relative effectiveness of all relevant interventions using rigorous statistical methods of quantitative assessment, even in the absence of head-to-head comparisons.

2020-05-20
Claims Database Analyses Brochure

Claims database analyses can provide insight on pharmaceutical and medical services utilization associated with a specific diagnosis, disease or treatment in routine clinical practice.

2020-04-29
In-Licensing Market Assessment Brochure

Looking for insight on quality candidates? PeriPharm can help companies seeking partnering and in-licensing opportunities by assessing a product’s potential performance on the Canadian market as part of the due diligence process.

2020-03-25
COVID-19 - Our Services are Maintainted

With the current situation, we recognize the importance of preventing the spread of COVID-19 while continuing to offer our services in pharmacoeconomics, outcomes research and market access. This is why all our employees will work from home until the situation recovers.

2020-02-25
Proud to be Sponsoring the 2020 CADTH Symposium!

PeriPharm is proud to sponsor the 2020 CADTH Symposium in Toronto, April 18 to 21.